Stroke & Cognitive Decline: IL-6 & Smoking Risk Identified | Manchester Research

Tracking changes in levels of an inflammation-related protein, interleukin-6 (IL-6), after a stroke may help identify individuals at increased risk of developing cognitive impairment – problems with memory and thinking – particularly among smokers, according to research from The University of Manchester. The findings, published in Alzheimer’s & Dementia, add to a growing body of evidence linking inflammation to long-term neurological outcomes following stroke.

Stroke, Inflammation, and Cognitive Decline: A Complex Relationship

Stroke is a leading cause of long-term disability, and cognitive impairment is a common and debilitating consequence. While the immediate effects of stroke are well understood, the processes that contribute to cognitive decline in the months and years following the event are more complex. Increasingly, research points to the role of inflammation in this process.

The Stroke IMPaCT study (Stroke – Immune Mediated Pathways and Cognitive Trajectory), a collaborative effort involving researchers in Europe and North America, is dedicated to understanding how inflammation and immune responses contribute to post-stroke cognitive decline. This latest research, conducted at Salford Royal Hospital within the Northern Care Alliance NHS Foundation Trust, focused on IL-6, a protein known to be involved in inflammatory responses. The study measured IL-6 levels in stroke patients at multiple time points – shortly after the stroke, and again at 6-9 months and 18-21 months – alongside detailed cognitive assessments.

How IL-6 Levels Correlate with Cognitive Function

Researchers found that IL-6 levels typically increase immediately after a stroke, then decrease in most patients within 6-9 months. However, a significant subset of patients experienced persistently high or even rising IL-6 levels. These individuals were approximately eight times more likely to develop difficulties with thinking ability compared to those whose IL-6 levels returned to normal. This association suggests that sustained inflammation may play a critical role in the development of post-stroke cognitive impairment.

The study also revealed notable differences between smokers and non-smokers. Smokers exhibited a different pattern of IL-6 change after stroke, with evidence of longer-lasting inflammation. This prolonged inflammatory response was more strongly linked to problems with thinking and memory in smokers, highlighting a potential synergistic effect between smoking and inflammation in exacerbating cognitive decline. The University of Manchester notes that this ongoing inflammation was more strongly linked to problems with thinking and memory.

Understanding Interleukin-6 and its Role in the Body

Interleukin-6 is a cytokine – a type of protein that acts as a messenger between cells in the immune system. It plays a complex role in inflammation, both promoting and regulating inflammatory responses. While IL-6 is essential for fighting infection and initiating tissue repair, chronic elevation of IL-6 has been implicated in a variety of chronic diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders.

In the context of stroke, the initial increase in IL-6 is likely a natural response to brain injury. However, the persistence of high IL-6 levels may indicate a dysregulated inflammatory response that contributes to neuronal damage and cognitive decline. The precise mechanisms by which IL-6 affects cognitive function after stroke are still being investigated, but it is thought to involve disruption of synaptic plasticity – the brain’s ability to form new connections – and increased oxidative stress.

Study Design and Limitations

The research involved a longitudinal study design, meaning that patients were followed over time, allowing researchers to assess the relationship between changes in IL-6 levels and subsequent cognitive outcomes. Plasma IL-6 and other inflammatory markers were measured within 96 hours of an ischemic stroke, and at 6-9 and 18-21 months, alongside cognitive assessment. Adjusted regression models were used to examine associations between inflammatory factors and cognition.

It’s important to note that this study demonstrates an association between IL-6 levels and cognitive impairment, but it does not prove causation. Other factors, such as the severity of the stroke, pre-existing health conditions, and genetic predisposition, may also contribute to cognitive decline. The study population was limited to patients treated at a single hospital, which may limit the generalizability of the findings. The researchers acknowledge that further studies are needed to confirm these findings in larger and more diverse populations.

Implications for Post-Stroke Care and Future Research

These findings suggest that monitoring IL-6 levels after stroke could potentially identify individuals at higher risk of cognitive impairment, allowing for earlier intervention and personalized management strategies. However, it is crucial to emphasize that IL-6 testing is not currently a standard part of post-stroke care. More research is needed to determine the optimal timing and frequency of IL-6 measurements, as well as the clinical utility of this approach.

The study also highlights the importance of smoking cessation for stroke survivors. Given the observed link between smoking, prolonged inflammation, and cognitive decline, encouraging smokers to quit could be a valuable component of post-stroke rehabilitation programs.

What’s on the Horizon?

Researchers are now exploring potential therapeutic strategies to modulate the inflammatory response after stroke. These include investigating the use of anti-inflammatory medications and lifestyle interventions, such as exercise and diet, to reduce IL-6 levels and protect cognitive function. Further research is also needed to understand the underlying mechanisms by which smoking exacerbates inflammation and cognitive decline after stroke, potentially leading to the development of targeted interventions for smokers. The NIHR Manchester Biomedical Research Centre supported this research as part of its Integrative Cardiovascular Medicine Theme, indicating ongoing commitment to this area of study.